Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1084 results about "Lipid metabolism" patented technology

Lipid metabolism is the synthesis and degradation of lipids in cells, involving the breakdown or storage of fats for energy and the synthesis of structural and functional lipids, such as those involved in the construction of cell membranes. In animals, these fats are obtained from food or are synthesized by the liver. Lipogenesis is the process of synthesizing these fats. The majority of lipids found in the human body from ingesting food are triglycerides and cholesterol. Other types of lipids found in the body are fatty acids and membrane lipids. Lipid metabolism is often considered as the digestion and absorption process of dietary fat; however, there are two sources of fats that organisms can use to obtain energy: from consumed dietary fats and from stored fat. Vertebrates (including humans) use both sources of fat to produce energy for organs such as the heart to function. Since lipids are hydrophobic molecules, they need to be solubilized before their metabolism can begin. Lipid metabolism often begins with hydrolysis, which occurs with the help of various enzymes in the digestive system. Lipid metabolism also occurs in plants, though the processes differ in some ways when compared to animals. The second step after the hydrolysis is the absorption of the fatty acids into the epithelial cells of the intestinal wall. In the epithelial cells, fatty acids are packaged and transported to the rest of the body.

Lipid metabolism regulators in plants

The present invention is directed to novel nucleic acid and amino acid sequences associated with the metabolism of seed storage compounds in plants. A novel discovery described herein lies in the identification of the nucleic acid sequences that encode the wri1 genetic locus in Arabidopsis thaliana, and lipid metabolism regulator (LMR) polynucleotide sequences contained therein. Preferably, the seed storage compounds are lipids, fatty acids, starches or seed storage proteins.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV

Effects of apolipoprotein B inhibition on gene expression profiles in animals

Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.
Owner:KASTLE THERAPEUTICS LLC

Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota

ActiveUS20110280840A1Increased use of antibioticIncreasing adult height and muscle massBiocideMetabolism disorderIntestinal microorganismsBone formation
The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics / anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.
Owner:NEW YORK UNIV

Method of regulating glucose metabolism, and reagents related thereto

The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and / or atherosclerosis.
Owner:1149336 ONTARIO +2

Linked biaryl compounds

Compounds, compositions and methods that are useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. In particular, the invention provides compounds which modulate the expression and / or function of proteins involved in lipid metabolism, inflammation and cell proliferation. The subject compounds are linked biaryl compounds.
Owner:AMGEN INC +1

Treating pain, diabetes, and disorders of lipid metabolism

Disclosed is a method of treating a disease or condition (e.g., pain, diabetes or disorders of lipid metabolism) comprising administering an azetidine derivative of the formula I selected from the group consisting of the compounds defined by Tables 1, 2, 3a, 3b, 3c, 3d and 4a.
Owner:SCHERING CORP

Pyrrolo[1,2-b]pyridazine derivatives

Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
Owner:JAPAN TOBACCO INC

Compositions and methods for apo-b48 and apo-b100 assay

The invention concerns compositions and methods for assay or detection of apolipoprotein-B48 in samples. In particular, it concerns a method for differential measurement of apolipoprotein-B48 (“Apo-B48”) and apolipoprotein-B100 (“Apo-B100”) in biological samples. The invention also concerns synthetic products of Apo-B100, the corresponding antibodies, kits containing same, and their uses for detecting, differentially quantifying and / or recording an amount of Apo-B48 and / or Apo-B100 in a sample, or for quantifying and / or recording atherogenic lipoparticles in a sample. The products, materials and kits hereinabove can also be used for differentially modulating the levels of Apo-B48 and / or Apo-B100 or their activity, in vitro or in vivo, and for regulating lipid metabolism in a subject.
Owner:GENFIT SA

Compositions and foods for improving lipid metabolism

It is intended to provide compositions and foods for use in the treatment, prophylaxis, or amelioration of diseases or symptoms which can be treated, prevented or ameliorated by activating PPAR, in particular, insulin resistant diabetes and hyperlipidemia. Namely, medicinal compositions usable in treating, preventing or improving diseases or symptoms which can be treated, prevented or ameliorated by activation PPAR which contain humulones, isohumulones or lupulones or pharmaceutically acceptable salts or solvates thereof.
Owner:KIRIN BREWERY CO LTD

Glucagon antagonists/inverse agonists

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and / or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
Owner:PFIZER INC

Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes

The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions.
Owner:TRUE HEALTH IP LLC

Method for the production of polyunsaturated fatty acids

The present invention relates to a process for producing polyunsaturated fatty acids in an organism by introducing nucleic acids into the organism which code for polypeptides having acyl-CoA:lysophospholipid a cyltransferase activity. Advantageously, these nucleic acid sequences may, if appropriate together with further nucleic acid sequences coding for biosynthesis polypeptides of the fatty acid or lipid metabolism, be expressed in the transgenic organism. The invention furthermore relates to the nucleic acid sequences, to nucleic acid constructs comprising the nucleic acid sequences of the invention, to vectors comprising the nucleic acid sequences and / or the nucleic acid constructs and to transgenic organisms comprising the abovementioned nucleic acid sequences, nucleic acid constructs and / or vectors. A further part of the invention relates to oils, lipids and / or fatty acids produced by the process of the invention and to their use.
Owner:BASF PLANT SCI

Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
Owner:EASTERN MICHIGAN UNIVERSITY +1

Plant acyltransferases specific for long-chained, multiply unsaturated fatty acids

The present invention relates to a process for the production of long-chain polyunsaturated fatty acids in an organism by introducing, into the organism, nucleic acids which code for polypeptides with acyl transferase activity. These nucleic acid sequences, if appropriate together with further nucleic acid sequences which code for polypeptides of the fatty acid or lipid metabolism biosynthesis, can advantageously be expressed in the organism. Furthermore, the invention relates to a method for the production of oils and / or triacylglycerides with an elevated content of long-chain polyunsaturated fatty acids.The invention furthermore relates to the nucleic acid sequences, nucleic acid constructs, vectors and organisms comprising the nucleic acid sequences according to the invention, vectors comprising the nucleic acid sequences and / or the nucleic acid constructs and to transgenic organisms comprising the abovementioned nucleic acid sequences, nucleic acid constructs and / or vectors.A further part of the invention relates to oils, lipids and / or fatty acids produced by the process according to the invention and to their use.
Owner:UNIV OF BRISTOL

Starch sub-types and lipid metabolism

A method is provided for regulating carbohydrate and fat metabolism is an individual which method comprises replacing a proportion of the individual's daily carbohydrate intake with resistant starch and a proportion of the individual's saturated fat intake with unsaturated fat. Also provided are compositions comprising resistant starch and unsaturated fats and methods for making and using the same
Owner:PENFORD AUSTRALIA

Polynucletides that control delta-6 desaturase genes and methods for identifying compounds for modulating delta-6 desaturase

InactiveUS20040053234A1Facilitate discovery identificationHigh viscositySugar derivativesPeptide/protein ingredientsDiseaseNucleotide
The present invention relates to polynucleotides that control desaturase genes and to drug screening assays for identifying pharmaceutially active compounds for use in the treatment of diseases involving abnormal lipid metabolism including diabetic neuropathy, by utilizing fatty acid desaturase enzymes and the genes which encode them as targets for intervention. The drug screening method identifies nucleotides, proteins, compounds and / or other pharmacological agents, which effectively modulate the activity of desaturase enzymes or regulate the level of expression of the desaturase genes.
Owner:XENON PHARMACEUTICALS INC

Combination therapy for controlling appetites

InactiveUS20050101542A1Reduce appetiteReduce and control appetiteBiocideCarbohydrate active ingredientsAppetite reducingCombination therapy
The invention provides methods and pharmaceutical compositions for administering a PPARα agonist (e.g., OEA-like agonist, OEA-like compound), an OEA-like appetite reducing compound, or a FAAH inhibitor and a CB1 cannabinoid receptor antagonist to a subject in order to reduce the consumption or ingestion of food, ethanol or other appetizing substances as well as in treating appetency disorders related to the excess consumption of food, ethanol, and other appetizing substances. The combination therapy can also be useful for reducing body fat or body weight and modulating lipid metabolism.
Owner:RGT UNIV OF CALIFORNIA

Method for preparing jerusalem artichoke beverage

The preparation method of girasole beverage includes three technological process steps: 1. preparation of girasole hydrolyzate; 2. preparation of osmanthus flower extract; and 3. blending, packaging and sterilizing. The girasole hydrolyzate, osmanthus flower extract, phosphoric acid and citric acid are mixed according to the mixing ratio of 100:(10-12):3:(4-6), then water is added according to the ratio of the above-mentioned mixed material liquor and water of 1:(50-60), uniformly stirred, bottled, capped and sterilized so as to obtain the invented product with rice nutrients and several health-care functions of reproducing bifidobacteria in human body, inhibiting the growth of intestinal salmonella and spilage organism, raising immunity of human body and reducing blood-lipid, etc.
Owner:林杨

Peptides, derivatives and analogs thereof, and methods of using same

InactiveUS20070087971A1Promoting beta cell regenerationIncrease satietyOrganic active ingredientsSenses disorderHuman Proislet PeptideProgenitor
Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and / or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
Owner:CUREDM GRP HLDG

Probiotic propionibacterium

The present invention relates to probiotic Propionibacterium strains and their use in the preparation of probiotic supplements and foods. The invention relates to the provision of Vitamin B12, propionic acid, folacin and bacteriocins by probiotic strains, stimulation of bifidobacteria growth, production of favourable effects on the lipid metabolism and on the immune system of hosts through immunostimulation, immunomodulation or use of a probiotic strain as an adjuvant, reduction of homocysteine and β glucuronidase and the prevention, treatment or amelioration of conditions associated with a need for these activities. The probiotic bacteria of the invention can be used in humans or other animals. In at least some applications, the bacteria can be used dead and parts rather than whole cells may be used. The present invention also relates to the preparation of vaccines for use in protecting patients from infectious diseases, in particular tuberculosis.
Owner:UNIV OF NEWCASTLE RES ASSOCS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products